{{NoteTA|G1=Chemistry|G2=Medicine}}
{{Drugbox
| verifiedrevid = 608094053
| IUPAC_name = ''(R)-N-methyl-1-phenyl-propan-2-amine''
| image = Levomethamphetamine.svg
| image2 = Levomethamphetamine.gif
<!--Clinical data-->
| tradename = 
| legal_CA = Schedule I
| legal_UK = Class A
| legal_US = {{tsl|en|Controlled Substances Act#Schedule II drugs||Schedule II}};特定配方為[[非处方药|OTC]]
| legal_UN = Psychotropic Schedule II
| legal_DE = Anlage II
| routes_of_administration= ''醫用'' :吸入(鼻腔)<br>''娛樂用'' :口服 靜脈注射, insufflation,吸入 栓劑
<!--Pharmacokinetic data-->
| metabolism = [[肝臟|肝臟]]
| excretion = [[腎|腎]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 33817-09-3 
| PubChem = 36604
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 33634
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 44RAL3456C
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02291
<!--Chemical data-->
| C=10 | H=15 | N=1
| molecular_weight = 149.2
| smiles = N([C@@H](Cc1ccccc1)C)C
| InChI = 1/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m1/s1
| InChIKey = MYWUZJCMWCOHBA-SECBINFHBQ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MYWUZJCMWCOHBA-SECBINFHSA-N
}}
{{medical}}


'''左旋甲基苯丙胺''' ('''levomethamphetamine''')<ref group = note>其他名字包含'''l-methamphetamine''', '''levodesoxyephedrine''', '''l-desoxyephedrine''', '''levmetamfetamine''' ([[国际非专利药品名称|INN]] and {{tsl|en|United States Adopted Name||USAN}}).</ref>又稱'''左旋甲基安非他命'''，是[[右旋甲基苯丙胺|右旋甲基苯丙胺]]的[[旋光異構體|旋光異構體]]。'''左旋甲基苯丙胺'''是[[擬交感神經|擬交感神經]][[血管收縮|血管收縮劑]]，是一些[[非处方药|非处方]](OTC) {{tsl|en|nasal decongestant|鼻腔去阻塞劑|鼻腔去阻塞吸入劑}}的活性成分{{#tag:ref|The active ingredient in some OTC inhalers in the United States is listed as ''levmetamfetamine'', the [[国际非专利药品名称|INN]] and {{tsl|en|United States Adopted Name||USAN}} of levomethamphetamine.<ref name="FDA levmetamfetamine">{{cite web|title=CFR TITLE 21: DRUGS FOR HUMAN USE: PART 341 -- COLD, COUGH, ALLERGY, BRONCHODILATOR, AND ANTIASTHMATIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE|url=https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=341.80|website=United States Food and Drug Administration|accessdate=7 March 2016|date=April 2015|quote=Topical nasal decongestants --(i) For products containing levmetamfetamine identified in 341.20(b)(1) when used in an inhalant dosage form. The product delivers in each 800 milliliters of air 0.04 to 0.150 milligrams of levmetamfetamine.|archive-date=2019-12-25|archive-url=https://web.archive.org/web/20191225081836/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=341.80|dead-url=no}}</ref><ref>{{cite encyclopedia| title=Levomethamphetamine| url=http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=36604#section=Identification| work=Pubchem Compound| publisher=National Center for Biotechnology Information| accessdate=2 January 2014| archive-date=2014-10-06| archive-url=https://web.archive.org/web/20141006215922/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=36604#section=Identification| dead-url=no}}</ref>|name="OTC levmetamfetamine"|group = "note"}}。

==藥理學特性==
左旋甲基苯丙胺可穿越[[血腦屏障|血腦屏障]]並作為{{tsl|en|TAAR1 agonist|痕量胺關聯受體1激動劑|TAAR1激動劑}}<ref name="TAAR1">{{cite encyclopedia | website=PubChem Compound | publisher=NCBI | url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?q=all&cid=36604#x291 | title=Levmetamfetamine | accessdate=17 October 2014 | archive-date=2014-10-18 | archive-url=https://web.archive.org/web/20141018010302/https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?q=all&cid=36604#x291 | dead-url=no }}</ref>，也作為{{tsl|en|norepinephrine releasing agent|去甲腎上腺素釋放劑}} (對[[多巴胺|多巴胺]]系統較無影響<ref name="PD" />)。它跟[[右旋甲基苯丙胺|右旋甲基苯丙胺]]一樣影響中樞神經系統，但作用方式不同<ref name="Melega" />。不同於右旋甲基苯丙胺，它在低劑量沒有造成[[欣快|欣快]]或[[成瘾|成瘾]]的特性<ref name="Melega">{{cite journal|last=Melega|first=WP|author2=Cho, AK |author3=Schmitz, D |author4=Kuczenski, R |author5= Segal, DS |title=l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine|journal=The Journal of Pharmacology and Experimental Therapeutics|date=February 1999|volume=288|issue=2|pages=752–8|pmid=9918585}}</ref><ref name="Mendelson2006">{{cite journal|vauthors=Mendelson J, Uemura N, Harris D, Nath RP, Fernandez E, Jacob P, Everhart ET, Jones RT |title=Human pharmacology of the methamphetamine stereoisomers|url=https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_2006-10_80_4/page/403 |journal=Clinical pharmacology and therapeutics|date=October 2006|volume=80|issue=4|pages=403–20|pmid=17015058|doi=10.1016/j.clpt.2006.06.013}}</ref><ref name="PD">{{cite journal|last=Kuczenski|first=R|author2=Segal, DS |author3=Cho, AK |author4= Melega, W |title=Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine|journal=The Journal of neuroscience : the official journal of the Society for Neuroscience|date=February 1995|volume=15|issue=2|pages=1308–17|pmid=7869099}}</ref>。在他的幾項生理作用中，[[血管收縮|血管收縮]]作用使其可用於去鼻腔阻塞噴劑<ref>{{cite web | author=Pray SW | title=Nonprescription Products to Avoid With Hypertension | work=uspharmacist.com | accessdate=17 October 2014 | url=http://www.uspharmacist.com/content/d/consult_your_pharmacist/c/19370/ {{Wayback|url=http://www.uspharmacist.com/content/d/consult_your_pharmacist/c/19370/ |date=20141030183542 }} | quote=Topical Nasal Decongestants</ref>。

左旋甲基苯丙胺的半衰期約為13.3至15小時，右旋甲基苯丙胺則為10.5小時<ref name="pmid17015058">{{cite journal  |vauthors=Mendelson J, Uemura N, Harris D, etal |title=Human pharmacology of the methamphetamine stereoisomers |journal=Clin. Pharmacol. Ther. |volume=80 |issue=4 |pages=403–20 |date=October 2006  |pmid=17015058 |doi=10.1016/j.clpt.2006.06.013 }}</ref>。

==參見==
*[[苯丙胺|苯丙胺]]
*[[甲基苯丙胺|甲基苯丙胺]]
*[[右旋甲基苯丙胺|右旋甲基苯丙胺]]

==注释==
<references group = note/>

==參考資料==
{{Reflist|2}}


[[Category:甲基苯丙胺|Category:甲基苯丙胺]]
[[Category:拟交感胺类|Category:拟交感胺类]]
[[Category:对映纯药物|Category:对映纯药物]]
[[Category:VMAT抑制药|Category:VMAT抑制药]]